Biolegend, 100748, Brilliant Violet 711™ anti-mouse CD8a Antibody, 500microl

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.
500microl
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: Mouse thymus or spleen
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 711™ under optimal conditions.
Concentration: µg sizes: 0.2 mg/mLµL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. For immunofluorescent staining using µl sizes, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.Brilliant Violet 711™ excites at 405 nm and emits at 711 nm. The bandpass filter 710/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 711™ is a trademark of Sirigen Group Ltd.Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser: Violet Laser (405 nm)
Application Notes: Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).
Application References(PubMed link indicates BioLegend citation): Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP) Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete) Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP) Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block) Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC) Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC) Shih FF, et al. 2006. J. Immunol. 176:3438. (FC) Kamimura D, et al. 2006. J. Immunol. 177:306. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete) Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed Lee CH, et al. 2009. Clin. Cancer Res. PubMed Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed Guo Y, et al. 2008. Blood 112:480. PubMed Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed Kenna TJ, et al. 2008. Blood 111:2091. PubMed Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed Medyouf H, et al. 2010. Blood 115:1175. PubMed Riedl P, et al. 2009. J. Immunol. 183:370. PubMed Apte SH, et al. 2010. J. Immunol. 185:998. PubMed Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed Cui L, et al. 2015. J Control Release. 206:220. PubMed Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations: Bruand M, et al. 2021. Cell Reports. 36(3):109412. PubMed Hajnik RL, et al. 2022. Sci Transl Med. 14:eabq1945. PubMed Christian DA, et al. 2022. Sci Immunol. 7:eabq7432. PubMed Lo WL, et al. 2023. Nat Immunol. 24:676. PubMed Tong L, et al. 2023. Sci Adv. 9:eade5041. PubMed Corria-Osorio J, et al. 2023. Nat Immunol. 24:869. PubMed Liu J, et al. 2023. Nat Commun. 14:2806. PubMed Li F, et al. 2022. Mediators Inflamm. 2022:5782922. PubMed Qi X, et al. 2022. FASEB J. 36:e22250. PubMed Klaus T, et al. 2022. JCI Insight. 7: . PubMed Cheng H, et al. 2023. Nat Metab. 5:314. PubMed Jerome JR, et al. 2023. Int J Mol Sci. 24: . PubMed Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed Hailemichael Y, et al. 2022. Cancer Cell. 40:509. PubMed Aggen DH, et al. 2020. Clin Cancer Res. . PubMed Israelow B, et al. 2020. bioRxiv. . PubMed Miller CM, et al. 2020. J Virol. 94:00:00. PubMed Effern M, et al. 2022. STAR Protoc. 3:101038. PubMed Shapiro MR, et al. 2020. Front Immunol. 1.972222222. PubMed Yilmaz B, et al. 2021. Cell Host Microbe. 29(4):650-663.e9. PubMed Stathopoulou C, et al. 2020. Immunity. 49(2):247-263.e7.. PubMed Duan Q, et al. 2021. Front Cell Dev Biol. 9:761193. PubMed Hu W, et al. 2021. Nat Immunol. 22:1163. PubMed Upadhyaya P, et al. 2021. J Immunother Cancer. 9:00. PubMed Wong E, et al. 2019. Cell Rep. 29:3047. PubMed Gawden‐Bone CM et al. 2018. Immunity. 49(3):427-437 . PubMed Chen JC et al. 2018. Cell systems. 7(1):92-103 . PubMed Tyagi AM et al. 2018. Immunity. 49(6):1116-1131 . PubMed Esmaili S, et al. 2021. Cell Systems. 12(5):432-445.e7. PubMed Wiede F, et al. 2021. Cancer Discov. Online ahead of print. PubMed Enriquez AB, et al. 2022. iScience. 25:104305. PubMed Mukherjee D, et al. 2022. Nat Commun. 13:3747. PubMed Zhang H, et al. 2020. Cancer Cell. 37(1):37-54.e9.. PubMed Super M, et al. 2021. Nat Biomed Eng. Online ahead of print. PubMed Yu M, et al. 2021. J Clin Invest. 131:. PubMed Paiva RS, et al. 2021. Eur J Immunol. 51:1968. PubMed Paiva RA, et al. 2021. Cell Reports. 35(2):108967. PubMed Dikiy S, et al. 2021. Immunity. 54(5):931-946.e11. PubMed Ramos CV, et al. 2020. Cell Reports. 32(3):107910. PubMed Kinsella S, et al. 2021. Cell Rep. 37:109789. PubMed Enriquez AB, et al. 2022. iScience. 25:104305. PubMed Pandey V, et al. 2021. eLife. 0.416666666666667. PubMed Crosse EI, et al. 2020. Cell Stem Cell. 27:822. PubMed Tyagi AM, et al. 2021. eLife. 10:00. PubMed Wang SS, et al. 2021. Biomedicines. 9:. PubMed Ulrich-Lewis JT, et al. 2022. Front Immunol. 13:861710. PubMed Frodermann V, et al. 2019. Nat Med. 25:1761. PubMed Campbell C et al. 2018. Immunity. 48(6):1245-1257 . PubMed Tang X, et al. 2022. Cell Rep. 41:111673. PubMed Faust HJ, et al. 2020. J Clin Invest. 130:5493. PubMed Devi S, et al. 2021. Immunity. 54(6):1219-1230.e7. PubMed Sun T, et al. 2017. Mucosal Immunol. 0.954861111. PubMed Chen YG, et al. 2020. Molecular Cell. 76(1):96-109. PubMed Zhang X, et al. 2020. Endocr Relat Cancer. 27:469. PubMed Holz LE et al. 2018. Cell reports. 25(1):68-79 . PubMed Zhang Y, et al. 2018. Nat Commun. 9:6. PubMed Goh PK, et al. 2022. Sci Adv. 8:eabk3338. PubMed Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed Melo-Silva CR, et al. 2021. PLOS Pathogens. 17(5):e1009593. PubMed Cho S, et al. 2018. Nat Commun. 9:2757. PubMed Blagih J, et al. 2020. Cell Rep. 30:481. PubMed Ma K, et al. 2022. iScience. 25:104347. PubMed Williams JB, et al. 2020. Nat Commun. 0.876388889. PubMed Dangaj D, et al. 2019. Cancer Cell. 35:885. PubMed Abdelfattah N, et al. 2022. Nat Commun. 13:767. PubMed Sjaastad FV, et al. 2020. Front Immunol. 11:1786. PubMed Lainé A, et al. 2021. Nat Commun. 12:6228. PubMed Israelow B, et al. 2020. J Exp Med. 217:00:00. PubMed Wang X, et al. 2021. Cell. 184:5357. PubMed Dai X, et al. 2021. Molecular Cell. 81(11):2317-2331.e6. PubMed Glodde N et al. 2017. Immunity. 47(4):789-802 . PubMed Hayashida E, et al. 2019. J Neuroinflammation. 0.789583333. PubMed Hoyer FF, et al. 2020. Immunity. 51(5):899-914.e7.. PubMed Fedele C, et al. 2021. J Exp Med. 218: . PubMed Loo Yau H, et al. 2021. Molecular Cell. 81(7):1469-1483.e8. PubMed Rosen SF, et al. 2022. Genome Med. 14:108. PubMed Lee HN, et al. 2022. JCI Insight. 7:. PubMed Culina S, et al. 2015. Diabetes. 64: 3532 - 3542. PubMed Heyde A, et al. 2021. Cell. 184(5):1348-1361.e22. PubMed Yun JH, et al. 2021. JCI Insight. 6:. PubMed Strait AA, et al. 2021. Commun Biol. 4:1005. PubMed Spath S, et al. 2022. iScience. 25:104998. PubMed Effern M, et al. 2020. Immunity. 53(3):564-580.e9. PubMed Mitchell LA, et al. 2019. Oncotarget. 10:2252. PubMed Samuelson DR, et al. 2021. Commun Biol. 4:997. PubMed
RRID: AB_11219594 (BioLegend Cat. No. 100747) AB_2563510 (BioLegend Cat. No. 100759) AB_2562100 (BioLegend Cat. No. 100748)
Structure: Ig superfamily, CD8α chain, 34 kD
Distribution: Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells
Function: Co-receptor for TCR
Ligand/Receptor: MHC class I molecule
Antigen References: 1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Zamoyska R. 1994. Immunity 1:243. 3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.
Gene ID: 12525
UniProt: View information about CD8alpha on UniProt.org
Clone: 53-6.7
Regulatory Status: RUO
Other Names: T8, Lyt2, Ly-2
Isotype: Rat IgG2a, κ